|
Session 135
Poster Abstracts
New Mechanisms of HIV-1 Drug Resistance
Monday, 1-4 pm
Room: Hall B |
| 847 |
I132M in HIV-1 Reverse Transcriptase Confers NNRTI Resistance but NRTI Hypersusceptibility
Zandrea Ambrose*1, C W Sheen1, D Nissley2, and N Sluis-Cremer1
1Univ of Pittsburgh Sch of Med, PA, US and 2SAIC-Frederick, MD, US |
| 848 |
High Phenotypic Resistance to AZT Correlates with an Increased Availability of Pre-translocated Complexes throughout the Viral Genome
Brian Scarth* and M Gotte
McGill Univ, Montreal, Canada |
849
 |
Introduction of the 64/65 Nucleotide Polymorphisms of Subtype C HIV-1 into Subtype B HIV-1 Selects for the K65R Mutational Pathway in Cell Culture
Cedric Invernizzi*, D Coutsinos, D Moisi, M Oliveira, B Spira, B Brenner, and M Wainberg
McGill Univ AIDS Ctr, Montreal, Canada |
850
|
Effect of Different Enfuvirtide-resistance Mutations on Variability of the Rev Responsive Element and the rev Gene in Patients on Enfuvirtide Treatment
Eva Poveda*, M Gonzalez, V Briz, J Gonzalez-Lahoz, and V Soriano
Hosp Carlos III, Madrid, Spain |
| 851 |
The Pressure Imposed by T-20 Selects Mutations also in the Regulatory Protein Rev
Valentina Svicher*1, R D'Arrigo2, C Alteri1, M Trignetti1, S Dimonte1, A Callegaro3, S Lo Caputo4, S Aquaro5, P Narciso2, and C F Perno2
1Univ of Tor Vergata, Rome, Italy; 2Natl Inst of Infectious Diseases, L Spallanzani, Rome, Italy; 3Hosp Riuniti, Bergamo, Italy; 4Hosp Santa Maria Annunziata, Florence, Italy; and 5Univ of Calabria, Rende, Italy |
| 852 |
Impaired Replication Conferred by the N43D Gp41 Mutation Could Be Restored by Changes in the Gp120 Protein
Cecilia Cabrera*1, S Marfil1, E Garcia1, L Ruiz1, M Bofill2, B Clotet1, and J Blanco1
1Fndn irsiCaixa, Badalona, Spain and 2ICREA, Barcelona, Spain |
853
|
Discordant Effects of Gag Cleavage Site Mutations on the IC50 of Protease Inhibitors and on HIV Replicative Capacity
Romina Quercia*1, E Dam1,2, D Descamps3, X Duval3, A Hance1, and F Clavel1
1INSERM U552, Paris, France; 2Eurofins-Viralliance, Paris, France; and 3Hosp Bichat-Claude Bernard, Paris, France |
854
|
Prevalence, Mutational Patterns, and Phenotypic Correlates of the L76V Protease Mutation in Relation to LPV-associated Mutations
Michael Norton*1, T Young1, N Parkin2, D Tokimoto1, L Lu1, T Pilot-Matias1, E Stawiski2, K Stewart1, D Kempf1, and R Sibtain1
1Abbott Labs, Abbott Park, IL, US and 2Monogram Biosci, South San Francisco, CA, US |
855
|
A General Method for Identifying Treatment-selected Resistance Directly from Clinical Records Predicts New Cross-class HIV Reverse Transcriptase Mutations Arising from Inhibitor Combinations
Richard Belew*1, M Chang1, J Fessel2, D Looney3, C Mathews4, S Y Rhee5, R Shafer5, and J Wong6
1Univ of California, San Diego, US; 2Kaiser Permanente, Oakland, CA, US; 3VA Hlthcare System, San Diego, CA, US; 4Owen Clin, Univ of California, San Diego, US; 5Stanford Univ, Palo Alto, CA, US; and 6VAMC and Univ of California, San Francisco, US |
856
|
Tracing Pathways of Resistance to Reverse Transcriptase Inhibitors from Sequencing Mixtures in HIV-1
Art Poon*1, D Richman1,2, and S Frost1
1Univ of California, San Diego, US and 2VA Hlthcare System, San Diego, CA, US |
| 857 |
HIV-1 Vif Mutants with Suboptimal Anti-APOBEC Activity Facilitate Emergence of Drug Resistance
L Mulder, A Harari, and Viviana Simon*
Mt Sinai Sch of Med, New York, NY, US |
| 858 |
APOBEC-mediated Sequence Editing and Epidemiological Surveillance of Transmitted HIV-1 Drug Resistance
Robert Gifford*, S Y Rhee, N Eriksson, T Liu, M Kiuchi, A Das, and R Shafer
Stanford Univ, Palo Alto, CA, US |
|
